Document # 49044IM1
Revision 7.5 14
Dated February 16, 2017
* Second-wave Inhibited
** Type 2B and Platelet-type von Willebrand increased at low concentration 0.2 -0.6 mg/mL. In addition, when cryoprecipitate is
added to test sample from patient with Platelet-Type [pseudo] VWD, enhanced response to low concentration Ristocetin will
continue, a Type 2B patient will show no response.
7
*** To distinguish between von Willebrand & Bernard Soulier, add normal plasma or cryoprecipitate to patient sample, vW patient
will respond, Bernard Soulier will not.
19
Key: A – Absent H – Hyper N – Normal R - Reduced
(Compared to Normal Ranges)
AGGREGATION RESPONSE WITH SELECTED ABNORMALITIES
Reagent
Final
Concentration
Aspirin Effect
Von Willebrand &
Bernard Soulier
Storage Pool/
Secretion Defect
Glanzmann's Thrombasthenia
ADP
5 – 10 µ
µµ
µM
N, R *
N N, R * A
Arachidonic Acid 0.5 mM A N N A
Collagen
1 – 5 µ
µµ
µg/mL
1 or 2
µ
µµ
µg/mL
5 µ
µµ
µg/mL
N
N
A
Epinephrine
10 - 50 µ
µµ
µM
R* N R * A
Ristocetin
0.5 – 1.5
mg/mL
Qualitative
Defect
** A,R,H ***
N N
To Next Page